NeoGenomics, Inc. ( NeoGenomics)

Primary tabs

NeoGenomics's picture

Management

Contact Address

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing. The Company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing.

NeoGenomics press release, blog etc

Wed, 05/28/2025 - 18:41 NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
Fri, 05/23/2025 - 09:03 NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
Tue, 04/22/2025 - 15:24 NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
Wed, 04/02/2025 - 17:39 Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
Tue, 03/18/2025 - 14:22 NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
Mon, 03/10/2025 - 15:07 NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
Wed, 01/15/2025 - 16:02 NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
Tue, 01/14/2025 - 15:38 Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Fri, 12/13/2024 - 13:52 NeoGenomics Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
Fri, 11/22/2024 - 04:35 NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
Thu, 06/13/2024 - 14:48 Fort Myers Mayor to Proclaim June as NeoGenomics Commitment to Cancer Month
Wed, 05/29/2024 - 21:39 NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
Sun, 12/04/2022 - 19:57 NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fri, 11/18/2022 - 11:41 NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
Thu, 10/13/2022 - 06:15 NeoGenomics Schedules its Third Quarter 2022 Earnings Release for November 8, 2022
Thu, 09/29/2022 - 15:01 NeoGenomics Hurricane Ian Emergency Response
Mon, 05/16/2022 - 07:49 NeoGenomics Appoints Lynn Tetrault Interim CEO
Thu, 05/05/2022 - 16:49 NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
more

InfoBox

HomePagewww.neogenomics.com
Twittertwitter.com/NeoGenomics
LinkedInwww.linkedin.com/company/neogenomics-laboratories